Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alkermes Expects Gradual Ramp-Up For Lybalvi Launch

Executive Summary

Alkermes’ combo pill of olanzapine and samidorphan gets US FDA approval; company predicts $10m first-year sales as schizophrenia/bipolar patients cycle through treatment options, including generics.

You may also be interested in...



Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value

After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses. 

Psychiatric Disorders Markets: Depression, Bipolar Disorder And Schizophrenia

PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.

Alkermes Thinks Nemvaleukin Could Succeed Where Other IL-2 Candidates Have Failed

On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel